Crossmark

High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Crossref DOI link: https://doi.org/10.1007/s13555-025-01358-6

Published Online: 2025-03-13

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shams, Kave

Montgomery, Jennifer

Morley, Jason

Gerasimaviciute, Vaiva

Seesaghur, Anouchka

Neasham, David

Tran, Kathy V.

Cordey, Myriam

Taylor, Andrew
License Information

Text and Data Mining valid from 2025-03-13

Version of Record valid from 2025-03-13
More Information

Article History

Received: 26 November 2024

Accepted: 3 February 2025

First Online: 13 March 2025

Declarations

:

: Kave Shams has no conflicts of interest to disclose. Jennifer Montgomery, Jason Morley, Vaiva Gerasimaviciute, Anouchka Seesaghur, David Neasham, Kathy V. Tran, Myriam Cordey, Andrew Taylor are employees of Amgen and hold Amgen stock. Myriam Cordey is a former employee of Celgene.

: BADBIR was approved by the National Health Service Research Ethics Committee North West England []. Patients provide written informed consent for their participation in the registry using the BADBIR registry enrolment consent form. The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments (guideline requirement).

Document is current

Any future updates will be listed below